Tetratherix (ASX:TTX) has taken a significant step forward in the development of its prostate cancer technology, advancing its Tutelix spacer toward an international pivotal trial following encouraging early clinical results and the successful completion of a Series A capital raise by its joint venture partner.
The company reported promising outcomes from an early human study evaluating the Tutelix spacer, a device designed to improve the safety and effectiveness of radiation therapy for prostate cancer patients.
The technology is injected between the prostate and rectum to create space that protects the rectum from radiation exposure during treatment. In the initial study, Tutelix maintained its shape, stayed precisely where it was injected, and produced no safety concerns for participating patients.
Encouraged by these results, the development program is now moving toward a larger international trial to be conducted in both Australia and the United States.
The transition to this next stage has been accelerated by a recent Series A capital raise completed by Tutelix Pty Ltd, the joint venture responsible for advancing the technology. The funding round, led by a specialist medical technology venture capital firm and supported by a syndicate of influential clinical experts, has brought the venture's total capital raised to approximately $5 million.
The involvement of leading physicians in the United States is particularly significant for the program’s future. Many of the joint venture’s shareholders are US-based key opinion leaders in urology and radiation oncology, a group that can play an important role in validating the technology and accelerating adoption once regulatory approval is achieved. Their engagement is expected to provide immediate presence in the US market and help build early commercial momentum.
Rectal spacers have become an increasingly important tool in modern prostate cancer treatment. Radiation therapy is one of the most common treatments for the disease, but the close proximity of the rectum to the prostate means that the surrounding tissue can receive unwanted radiation. A spacer, made from a soft absorbable material, temporarily pushes the rectum away from the prostate, reducing radiation exposure and lowering the risk of both short and long-term side effects. This separation can also allow doctors to deliver higher radiation doses over shorter treatment periods, sometimes reducing therapy schedules to just four to six weeks.
Today’s prostate spacers are typically delivered during a short outpatient procedure guided by ultrasound imaging. Clinicians insert a needle through the perineum and inject the spacer between the prostate and rectum. Some doctors first inject saline to open the tissue plane in a step known as hydrodissection.
Existing spacer technologies each come with practical limitations. One commonly used product requires several solutions to be mixed immediately before use and must be injected within a short time window before it hardens. Another product is delivered in ready-to-use syringes, but it cannot be used after hydrodissection because the saline can dilute the gel, reducing its effectiveness.
Tutelix has been designed to address these challenges. The spacer arrives ready for use, requires no mixing before insertion, and does not obstruct the ultrasound visibility of the needle during the procedure. It can also be used with or without hydrodissection, giving clinicians greater flexibility depending on their preferred technique. Once injected, the material forms a stable and cohesive space that gently pushes the rectum away from the prostate, helping optimise radiation dosing while maintaining clear visual control of the needle during placement.
Early clinical data for Tutelix have been encouraging. Twelve patients have so far received the spacer as part of the study, and in every case the device successfully created space, reducing the amount of radiation reaching the rectum. All participants have either completed or are nearing completion of their radiation treatment, and follow-up assessments up to six months after insertion have shown no safety concerns or adverse events related to the device.
Recruitment for the final three patients in the pilot study is expected to be completed during March 2026. In parallel, preparations are underway for the larger pivotal trial that will support regulatory clearance in the United States. The study design has already been confirmed with regulators, and ethics approval in Australia is expected shortly. Half of the patients will be enrolled in Australia, with the trial expected to begin before July 2026, while the remainder will be recruited in the United States over the following year.
Tetratherix chief executive Will Knox said the company views the progress as a major milestone for the technology and for its long-term commercial strategy. He noted that the backing of leading US interventional physicians provides a strong endorsement of the product’s clinical potential and its relevance to the world’s largest healthcare market.
Knox believes Tutelix has the potential to replace older technologies that can be complex to administer or produce inconsistent outcomes. By simplifying the procedure and enabling higher radiation doses over shorter treatment schedules, he said the device could significantly improve the treatment experience for patients while opening the door to meaningful participation in a rapidly growing global market.